← Back

Zhejiang DiAn Diagnostics Co

Dian Diagnostics Group Co.,Ltd. provides integrated medical diagnostics solutions with independent diagnostic services in China. The company offers laboratory supplies and kits; AI-assisted digital pathology diagnosis solutions, such as nucleic acid extraction and purification system, automatic liquid-based cytology slide preparation and staining system, digital pathology slide scanner, automated pathology slide staining system, genotyping DNA test kit, human papillomavirus nucleic acid detection kit, PCR system and detection system, and virus collection and preservation system; and multi-omics platform services. It also provides DP-TOF nucleic acid mass spectrometry solutions, including mass spectroscopy system, automatic sample processing system, respiratory pathogens multiple detection kit, and nucleic acid sample pretreatment reagent kit; and forensic drug testing products comprises diangio, hair drug trace tester and detector, and saliva and urine drug testing product series. In addition, the company offers diagnostic product supply, medical testing services, supply chain optimization, digital operation management, laboratory quality system construction, and professional cold chain logistics services. Further, it is involved in the research and development of diagnostic products; and vitro diagnostic reagents, as well as forensic identification, health management, and other fields. The company was formerly known as Zhejiang DIAN Diagnostics Co., Ltd. and changed its name to Dian Diagnostics Group Co.,Ltd. in November 2017. Dian Diagnostics Group Co.,Ltd. was founded in 1996 and is based in Hangzhou, China.

Price · split & dividend adjusted
News & notes moving 300244.CS
300244.CS4

迪安診断、2026年中間決算の純利益は2億3200万元、前年同期比2160.87%増

迪安診断が2026年中間決算を発表し、親会社株主に帰属する純利益は2億3200万元で、前年同期比2160.87%増となった。営業総収入は47億7300万元で前年同期比3.30%減、営業活動によるキャッシュ・フロー純流入額は2億5900万元で前年同期比6.59%減だった。最新の資産負債比率は37.97%で、前年同期より5.04ポイント低下した。粗利益率は30.12%で、2四半期連続で上昇した。希薄化後1株当たり利益は0.38元で、前年同期比2163.10%増となった。
Jiemian·6d続きを読む ▾
300244.CS

拓荊科技、上半期の純利益が1324.1%急増

拓荊科技は2026年上半期に営業収入29億1300万元を計上し、前年同期比49.06%増となった。上場企業株主に帰属する純利益は13億4300万元で、前年同期比1324.1%増。また、全株主を対象に10株当たり現金配当3.5元を実施する予定だ。迪安診断の上半期純利益は2億3200万元で、前年同期比2160.87%増。日科化学の純利益は3027万元で、前年同期比2518.58%増となった。中国平安の上半期における親会社株主に帰属する純利益は925億8500万元で、前年同期比36.1%増。寧滬高速は73億4100万元の現金で蘇錫常南部高速公司の株式100%を取得する予定だ。深科達によると、同社のストレージ機器事業は画期的な進展を遂げ、上半期に北米の有名HDDストレージメーカーから約5792万6000元の新規受注を獲得した。
上海证券报·6d続きを読む ▾